SCHEMBL17360600

SCHEMBL17360600

Nc1ncc(F)cc1-c1ccc(Oc2ncc(NC(=O)Nc3ccc(F)c(C(F)(F)F)c3)cn2)cc1

nearest known ligand 0.67

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 17/20 0.67
CDK8 P49336 2/20 0.59
RIPK1 Q13546 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17360519 0.94 NTRK1 (0.68) NTRK1
SCHEMBL17360219 0.93 NTRK1 (0.75) NTRK1CDK8
SCHEMBL17360574 0.93 NTRK1 (0.67) NTRK1
SCHEMBL17360380 0.91 NTRK1 (0.67) NTRK1CDK8
SCHEMBL17360218 0.91 NTRK1 (0.65) NTRK1
SCHEMBL17360551 0.90 NTRK1 (0.64) NTRK1
SCHEMBL17360131 0.90 NTRK1 (0.63) NTRK1
SCHEMBL17360125 0.89 NTRK1 (0.65) NTRK1
SCHEMBL17360254 0.89 NTRK1 (0.66) NTRK1
SCHEMBL17360123 0.89 NTRK1 (0.64) NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10765676-B2 Trk-inhibiting compound ONO PHARMACEUTICAL CO., LTD. (JP) 2020-09-08 US disclosed
US-20190231777-A1 Trk-INHIBITING COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2019-08-01 US disclosed
US-10300060-B2 Trk-inhibiting compound ONO PHARMACEUTICAL CO., LTD. (JP) 2019-05-28 US disclosed
US-20180256573-A1 Trk-INHIBITING COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2018-09-13 US disclosed
US-9993479-B2 Trk-inhibiting compound ONO PHARMACEUTICAL CO., LTD. (JP) 2018-06-12 US disclosed
US-20170340634-A1 Trk-INHIBITING COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2017-11-30 US disclosed
US-9763943-B2 Trk-inhibiting compound ONO PHARMACEUTICAL CO., LTD. (JP) 2017-09-19 US disclosed
US-20170027939-A1 Trk-INHIBITING COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2017-02-02 US disclosed
US-9498453-B2 Trk-inhibiting compound ONO PHARMACEUTICAL CO., LTD. (JP) 2016-11-22 US disclosed
US-9463192-B2 Trk-inhibiting compound ONO PHARMACEUTICAL CO., LTD. (JP) 2016-10-11 US disclosed
US-20160280684-A1 TRK-INHIBITING COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2016-09-29 US disclosed
US-20160000783-A1 Trk-INHIBITING COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2016-01-07 US disclosed
EP-2960234-A1 Trk-INHIBITING COMPOUND ONO Pharmaceutical Co., Ltd. (JP) 2015-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10300060-B2 Trk-inhibiting compound LTK, ROR1, TRPV1 NTRK1 33/4885CDK8 1285/4885RIPK1 825/4885
US-20180256573-A1 Trk-INHIBITING COMPOUND LTK, ROR1, TRPV1 NTRK1 33/4885CDK8 1285/4885RIPK1 825/4885
US-20160280684-A1 TRK-INHIBITING COMPOUND LTK, ROR1, TRPV1 NTRK1 33/4885CDK8 1285/4885RIPK1 825/4885
US-20160000783-A1 Trk-INHIBITING COMPOUND LTK, ROR1, TRPV1 NTRK1 33/4885CDK8 1285/4885RIPK1 825/4885
US-20190231777-A1 Trk-INHIBITING COMPOUND LTK, ROR1, TRPV1 NTRK1 33/4885CDK8 1285/4885RIPK1 825/4885
US-20170340634-A1 Trk-INHIBITING COMPOUND LTK, ROR1, TRPV1 NTRK1 33/4885CDK8 1285/4885RIPK1 825/4885
US-10765676-B2 Trk-inhibiting compound LTK, ROR1, TRPV1 NTRK1 33/4885CDK8 1285/4885RIPK1 825/4885
US-20170027939-A1 Trk-INHIBITING COMPOUND LTK, ROR1, TRPV1 NTRK1 33/4885CDK8 1285/4885RIPK1 825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.